Thyroxine I-131 is a radiolabeled thyroid hormone that has been studied as a diagnostic agent for thyroid cancer. In pharmacokinetic studies, Thyroxine I-131 shows broad tissue distribution and 99% of the ingested radiolabeled Thyroxine may be found in the skin, intestines, muscles, blood, bones, liver, and thyroid glands of rats.

Fiacitabine, also known as FIAC, is a pyrimidine nucleoside, which had been in phase II clinical trilas for the treatment Cytomegalovirus infections and Herpes simplex virus infections. However, these researches have been discontinued. It was also shown the inhibitor activity of FIAC against the DNA polymerase of hepadnaviruses.

Canthaxanthin is a keto-carotenoid pigment and potent lipid-soluble antioxidant widely distributed in nature. Canthaxanthin has been found in edible mushrooms green algae, bacteria, crustaceans, and bioaccumulates in fish such as carp, golden mullet, seabream and trash wrasse. Canthaxanthin is used to reduce sensitivity to sunlight (photosensitivity) experienced by people who have a rare genetic disease called erythropoietic protoporphyria (EPP). In these people, sunlight can cause skin reactions such as rash, itch, and eczema. Canthaxanthin is also used to reduce sun sensitivity caused by certain medications. Some people also try it for relieving itching caused by sun exposure. Canthaxanthin is associated with E number E161g and is approved for use as a food coloring agent in different countries, including the United States and the EU; however, it is not approved for use in Australia and New Zealand. It is generally authorized for feed applications in at least the following countries: US, Canada, EU. In the EU, canthaxanthin is allowed by law to be added to trout feed, salmon feed, and poultry feed. The European Union limit is 80 mg/kg of feedstuffs, 8 mg/kg feed for egg-laying hens and 25 mg/kg in feed for other poultry and salmonids.

Iodometomidate I-123, R- (also known as ) is phenylethylimidazole derivative studied as a diagnostic agent for adrenal imaging. Iodometomidate is a highly suitable tracer combining specific uptake in adrenocortical tissue with far lower radiation exposure compared to norcholesterol scintigraphy. Phase III clinical trial for Adrenal Gland Neoplasms imaging is currently ongoing.

Letimide is a new analgesic. It is a cyclic derivative of a salicylamide. The analgesic effect of this drug as determined in rats showed a higher potency than aspirin, but was without anti-inflammatory and antipyretic activity. Letimide is not a genotoxic agent according to the cytogenetic damage observed in vivo and in vitro, and would seem to justify other preclinical and clinical studies to confirm its lack of toxicity. Known adverse effects are headache and dizziness.

Delmadinone is a steroid with progestogenic, anti-androgenic and weak glucocorticoid action, synthesized in Syntex S.A. Acetate ester of delmadinone is used in veterinary under tradenames Tardak for cats and dogs for the treatment of excessive or aberrant sexual behaviour, including vagrancy, for the relief of prostatic hypertrophy, circum-anal tumors and for the treatment of certain forms of aggressiveness, nervousness, epileptiform seizures and corticosteroid-resistant pruritus. Delmadinone acetate blocks androgen receptors inhibit 5-reductase, which catalyzes the transformation of testosterone to the more potent androgen 5-dihydrotestosterone and decreases the production of testosterone by inhibiting gonadotropin release.

Sulfacecole is an isoxazolylsulfanilamide derivative patented by Hoffmann -La Roche, F., und Co., A.-G. as antibacterial agent.

Iosimide is synthetic, nonionic, monomeric contrast medium patented by Schering A.-G. In clinical trial Iosimide exhibited no differences in comparison with Ioxaglate with respect to the contrast, the neurological status or the liver or renal tolerance. In examining cardiovascular tolerance there is only a slight tendency toward liver changes with Iosimide. Examination of the general tolerance, however, shows a statistically significant lower incidence of sensation of heat and pain with iosimide than with ioxaglate.

SR 202 is an antagonist of peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity induced by troglitazone but not of basal PPARγ activity. It is selective for PPARγ, not affecting basal or agonist-induced transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). It inhibits PPARγ-dependent differentiation of preadipocyte 3T3-L1 cells in a dose-dependent manner. SR 202 (400 mg/kg) decreases the amount of weight gained and white adipose tissue mass accumulated by mice fed a standard or high-fat diet for ten weeks and is associated with lower PPARγ mRNA levels. It protects against high-fat diet-induced insulin resistance in wild-type mice and improves insulin sensitivity in ob/ob mice.